ONCY | Oncolytics Biotech Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9201 - 1.0000
52 Week Range	0.8500 - 2.3500
Beta	N/A
Implied Volatility	155.28%
IV Rank	N/A
Day's Volume	151,741
Average Volume	179,637
Shares Outstanding	76,986,000
Market Cap	73,752,588
Sector	Healthcare
Industry	Biotechnology
IPO Date	2001-10-05

Valuation
Profitability
Growth
Health
P/E Ratio	-3.42
Forward P/E Ratio	N/A
EPS	-0.28
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	Canada
Website	ONCY

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY's peers: BYSI, DMAC, GALT, IKT, KTRA, MIST, SCPH, MCRB, LIFE, XFOR, GRTX, TERN, DAWN, HOOK, CVAC, RETA, KRYS, VIR, PPCB, PRTA, XCUR

*Chart delayed

Analyzing fundamentals for ONCY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ONCY Fundamentals page.

Watching at ONCY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ONCY Technicals page.